{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166182844",
    "name" : "Annotation of DPWG Guideline for simvastatin and SLCO1B1",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : true,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1450415247,
        "date" : "2019-05-27T00:00:00-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450821034,
        "date" : "2019-10-07T18:33:59.696-07:00",
        "description" : "No changes based on August 2019 guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450963902,
        "date" : "2020-02-11T07:53:52.150-08:00",
        "description" : "Fixed links to 2018 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450963883,
        "date" : "2020-02-11T07:54:48.614-08:00",
        "description" : "Fixed table where said atorvastatin instead of simvastatin",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451221540,
        "date" : "2020-07-06T20:14:39.045-07:00",
        "description" : "fixed typo for 521 TC in the table",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451257900,
        "date" : "2020-08-31T17:39:51.853-07:00",
        "description" : "updated according to the August 2020 document",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451492980,
        "date" : "2021-09-08T00:00:00-07:00",
        "description" : "Added extended dosing guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704168,
        "date" : "2022-03-03T16:33:20.952-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451707501,
        "date" : "2022-03-08T10:44:03.380-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732808,
        "date" : "2022-03-28T09:57:34.711-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451733454,
        "date" : "2022-03-28T15:02:24.877-07:00",
        "description" : "Updated link to testing guidance page",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451741542,
        "date" : "2022-04-05T11:18:57.557-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451884694,
        "date" : "2022-09-16T14:40:40.933-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146456,
        "date" : "2023-07-03T13:39:48.995-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411560,
        "date" : "2024-03-18T00:00:00-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15113882,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2020","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf","crossReferences":[{"id":1451257580,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2020.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Variant",
        "id" : "PA166154579",
        "symbol" : "rs4149056",
        "name" : "rs4149056",
        "version" : 6
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA451363",
        "name" : "simvastatin",
        "version" : 24
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA134865839",
        "symbol" : "SLCO1B1",
        "name" : "solute carrier organic anion transporter family member 1B1",
        "version" : 49
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1450415244,
      "html" : "<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1450415245,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"august-2020-guideline-update\">August 2020 Guideline update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for simvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_August_2020.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf\">Dutch guidelines November 2020 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><em>SLCO1B1</em> 521 CC</td>\n<td>simvastatin</td>\n<td>When using simvastatin 80 mg/day, the risk of myopathy is increased 30-fold to 18% and the risk of severe myopathy is increased 48-fold to 12%. When using 40 mg/day, this risk is increased 7-fold to 1% and 11-fold to 0.68% respectively. The gene variation leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.</td>\n<td>1. Choose an alternative.<br/>Consider any additional risk factors for statin-induced myopathy.<br/>Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.<br/>Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.<br/>Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.</td>\n</tr>\n<tr>\n<td><em>SLCO1B1</em> 521 TC</td>\n<td>simvastatin</td>\n<td>When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39% and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.</td>\n<td>1. Choose an alternative.<br/>Consider any additional risk factors for statin-induced myopathy.<br/>Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.<br/>Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.<br/>Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.<br/>2. If an alternative is not an option:<br/>1. Avoid simvastatin doses exceeding 40mg/day.<br/>2. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_SLCO1B1_simvastatin_4055-4056.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_SLCO1B1_simvastatin_4055-4056.pdf\">Read for more information about this recommendation</a>, <a download=\"SLCO1B1.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/SLCO1B1.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_SLCO1B1_simvastatin_4055-4056.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_SLCO1B1_simvastatin_4055-4056.pdf\">DPWG risk analysis document</a> for simvastatin and SLCO1B1:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers genotyping before starting simvastatin 80 mg/day to be essential for drug safety. Genotyping must be performed before drug therapy has been initiated to guide drug selection. The KNMP Pharmacogenetics Working Group considers genotyping before starting simvastatin at a dose of 40 mg/day or lower to be beneficial for drug safety. It is advised to genotype the patient before (or directly after) drug therapy has been initiated to guide drug selection.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for simvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>521 CC</td>\n<td>simvastatin</td>\n<td>The genetic polymorphism leads to reduced simvastatin transport to the liver. This increases simvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.</td>\n</tr>\n<tr>\n<td>521 TC</td>\n<td>simvastatin</td>\n<td>The genetic polymorphism may lead to reduced simvastatin transport to the liver. This may increase simvastatin plasma concentrations and therefore the risk of myopathy.</td>\n<td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option:<br/>1. Avoid simvastatin doses exceeding 40 mg/day<br/>2. Advise the patient to contact their doctor in the event of muscle symptoms.</td>\n</tr>\n</tbody>\n</table>\n",
      "version" : 9
    },
    "version" : 14
  }
}